Advanced Biomed Inc.

This section discusses the material components of the executive compensation program for our named executive officers for the years ended June 30, 2026 and 2025.

Summary Compensation Table

The following table presents the compensation awarded to or earned by or paid to our current and former executive officers during the fiscal years ended June 30, 2026 and 2025.

Outstanding Equity Awards at Fiscal Year End

There were no outstanding equity awards as of June 30, 2026.

Share Incentive Plans

Effective March 30, 2023, our Stock Incentive Plan (the “2023 Plan”) was approved by our Board of Directors. Under the 2023 Plan, the Board of Directors may grant options or purchase rights to purchase Common Stock to officers, employees, and other persons who provide services to us or any related company. The participants to whom awards are granted, the type of awards granted, the number of shares covered for each award, and the purchase or exercise price, conditions and other terms of each award are determined by the Board of Directors, except that the term of the options shall not exceed 10 years. A total of 750,000 shares of our Common Stock are subject to the 2023 Plan and maybe either a qualified or non-qualified stock option. The shares issued for the 2023 Plan may be either treasury or authorized and unissued shares. As of June 30, 2026, we have granted no stock options to purchase any shares of our Common Stock under the 2023 Plan.

Employment Agreements with Our Named Executive Officers and Potential Payments Upon Termination or Change in Control

Xiaomin Chen. On April 28, 2026, we entered into an employment agreement with Dr. Xiaomin Chen, our Chief Executive Officer, pursuant to which Dr. Chen is entitled to a base salary of US$12,000 per month (US$144,000 per year) and discretionary bonuses as determined by our board of directors, and is eligible to participate in any future share incentive plan. If Dr. Chen’s employment is terminated by us without cause, he is entitled to severance equal to 12 months of base salary, a pro-rated bonus, 12 months of health insurance premiums and full vesting of outstanding equity awards; upon a change of control, he is entitled to 12 months of base salary, a pro-rated bonus and full vesting of equity awards; and if he resigns for good reason, he is entitled to 12 months of base salary. The agreement contains non-competition and confidentiality covenants.

Mingze Yin. We have entered into an employment agreement with Mingze Yin, our Chief Financial Officer, dated November 1, 2025, for a two-year term, renewable by mutual agreement subject to Board approval. Under the agreement, Mr. Yin is entitled to an annual salary of $120,000, payable in monthly installments of $10,000, and is eligible for an annual cash bonus at the discretion of the Board or its duly authorized committee.

Director Compensations

For the fiscal year ended June 30, 2026, we and our subsidiaries paid aggregate cash compensation of approximately $182,000 to our executive and non-executive directors as a group. Our Chief Executive Officer and our Chief Financial Officer are executive directors whose compensation were disclosed under “Item 11 - Executive Compensation-Summary Compensation Table.” We do not pay or set aside any amounts for pensions, retirement or other benefits for directors.

The following table shows the compensation paid to our non-employee directors during the year ended June 30, 2026.